
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MAHLY | OTC Markets | USD | Delayed | |
7459 | Tokyo | JPY | Delayed |
Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprising medical equipment and medical materials, and clinical diagnostic reagents for use from the pre-symptomatic stage; handles PMS services on contract for manufacturers; and invests in orphan drugs and other products. The company is also involved in the wholesale of cosmetics, daily necessities, and OTC pharmaceuticals; and animal health products for companion animals; and food processing raw materials for agriculture, fisheries, and livestock. In addition, it engages in the contract-based epidemiological studies, clinical studies, etc.; creation of a computerized medical supply database and master product databases for medical facilities; life and non-life insurance agency business; cleaning management; management and operation of distribution centers; commissioned delivery and worker dispatch business; planning, management, administration, and product and service development for the class A health dispensing pharmacies service brand; and distributes specialty pharmaceuticals. Further, the company is involved in contract logistics services; information provision services; health insurance claims review, medical coding dispatch, outsourcing and remote education; and creation of a medical supply database and master product databases for medical facilities. It serves hospitals, clinics, dispensing pharmacies, drugstores, home centers, convenience stores, supermarkets, discount stores, animal hospitals, livestock and fish producers, and processed food manufacturers. The company was formerly known as Mediceo Paltac Holdings Co., Ltd. and changed its name to Medipal Holdings Corporation in October 2009. Medipal Holdings Corporation was founded in 1898 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Yuji Sakon | - | 2012 | MD, GM of Administration Division & Director |
Shuichi Watanabe | 71 | 2000 | Chief Compliance Officer, CEO, President & Representative Director |
Toshihide Yoda | 60 | 2010 | Senior MD of Investor Relations, GM of Business Development Department & Director |
Shinjiro Watanabe | 51 | 2013 | GM of Information Systems Management Division & Director |
Imagawa Kuniaki | 62 | 2022 | Director |
Hiroshi Iwamoto | 65 | 2021 | Independent Outside Director |
Takuya Yoshida | 52 | 2023 | Director |
Yasuhiro Choufuku | 71 | 2016 | Executive VP & Representative Director |
Yoko Sanuki | 76 | 2019 | Outside Audit & Supervisory Board Member |
Mitsuko Kagami | 67 | 2014 | Independent Outside Director |
Toshio Asano | 73 | 2017 | Independent Outside Director |
Kuniko Shoji | 71 | 2018 | Independent Outside Director |
Toshio Hirasawa | 75 | 2015 | Full-time Auditor |
Masayuki Mitsuka | 71 | 2025 | Outside Audit & Supervisory Board Member |
Hatsuyoshi Ichino | 66 | 2023 | Outside Audit & Supervisory Board Member |
Imagawa Kuniaki | 64 | 2022 | Deputy Head of Pharmaceutical Business & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review